Pipeline expansion: Company advances first-in-class clinical pipeline to address large unmet medical needs in Atopic Dermatitis, Asthma, Inflammatory Bowel Disease, and Obesity

Platform scale: Company doubles down on its platform, delivering 12+ development candidates from life’s chemistry 4× faster and 10× cheaper than industry average

BOULDER, Colo.–(BUSINESS WIRE)–Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced three major milestones: the close of its $150 million oversubscribed Series D financing, enrolling of the first patient in a Phase 1b clinical trial for lead program ENV-294 in atopic dermatitis, and the appointment of former Pfizer Chief Scientific Officer and President of Worldwide R&D, Dr. Mikael Dolsten, to its Board of Directors.

The round was led by Premji Invest with participation from new and existing investors Baillie Gifford, Kinnevik, Lingotto Investment Management, Peakline Partners, FPV, Socium Ventures, Dimension, Level Ventures, Henry Kravis, IA Ventures, and Lux Capital. This follows a $150 million Series C closing in February that included Sanofi, bringing the company’s total funding to $517 million.

In just five years from seed financing, Enveda has scaled from platform proof-of-concept into one of the fastest-growing techbio companies, advancing a wholly-owned, internally generated pipeline of novel small molecules that now spans discovery through the clinic. Enveda’s rapid trajectory has been enabled by its proprietary chemical sequencer, the first platform to systematically decode previously inaccessible chemistry in living systems using machine learning and metabolomics.

“Enveda is proving that it’s possible to generate novel and first-in-class small molecule therapeutics at an unprecedented speed, scale, and efficiency,” said Akshay Rai, Principal, Healthtech and Biotech at Premji Invest. “We believe there is a large unexplored search space for novel medicines, and Enveda has built the platform to translate life’s chemistry into treatments that could be transformative for millions of patients across the globe. This team is turning breakthrough science into medicines at a pace that is exceptionally rare, and are on their way to building what could be an industry-defining company.”

The Series D funding will advance multiple clinical programs into Phase 1b and Phase 2 trials across diseases affecting more than 100 million adults in the U.S. alone. The funds will also support new IND filings in the coming months, positioning the company to deliver key clinical milestones across atopic dermatitis, asthma, inflammatory bowel disease, obesity, and more.

Key Clinical Milestone Highlights the Power of a Unique Approach

Nearly half of all oral medicines originate from molecules found in nature, yet it is estimated that 99% of nature’s chemical diversity remains unexplored due to the complexity and cost of isolating, identifying, and characterizing individual compounds. Enveda has built one of the world’s largest collections of natural samples and made its chemistry searchable, using AI that can analyze thousands of molecules at once and a fully automated high-throughput lab to map therapeutic properties. By putting billions of years of evolutionary intelligence into the hands of drug hunters for the first time, Enveda is accelerating the discovery of first-in-class medicines more than fourfold and pioneering a faster, more precise path to transformative therapies.

“At Enveda, we are learning from life’s chemical code,” said Viswa Colluru, Founder and CEO, Enveda. “Nature has been running the most sophisticated R&D program on Earth for billions of years, yet nearly all of its chemistry remains unexplored. By making this hidden language searchable and pairing it with AI, automation, and metabolomics, we are transforming how medicines are discovered. We’re building a generational company that changes the way the world understands and uses life’s chemistry, to deliver breakthroughs that can redefine medicine and transform industries.”

Today, Enveda has sixteen preclinical programs, more than a dozen development candidates, four IND-enabling programs, and one clinical program underway. This progress has been achieved in less time than it typically takes biotechs, which average more than seven years to bring their first new chemical entity into Phase 1 trials.

ENV-294, Enveda’s lead program, is a first-in-class, oral anti-inflammatory small molecule derived from nature, discovered entirely on its platform. This candidate represents a completely new chemical class with a novel mechanism of action. It demonstrates kinase inhibitor-like and steroid-like best-in-disease preclinical efficacy in inflammatory disease models and a safety profile similar to biologics in toxicology studies. The Phase 1b trial in patients with moderate to severe atopic dermatitis follows successful Phase 1a results in healthy volunteers, where ENV-294 demonstrated favorable safety and tolerability in patients, with no dose-limiting toxicities or serious adverse events.

Esteemed Industry Veteran Dr. Mikael Dolsten Joins Board

Dr. Dolsten, credited with advancing more than 150 drug candidates into clinical studies and 36 approvals during his tenure at Pfizer as Chief Scientific Officer and President of Worldwide R&D, joins Enveda’s Board of Directors. Dr. Dolsten’s career has been defined by bold scientific bets that changed the trajectory of human health, with a track record of leading groundbreaking science from research to market. “I’m proud to join Enveda, where the team has built the technology to harness the potential of life’s chemistry at scale,” said Dolsten.

About Enveda

Enveda is a biotechnology company that learns from life’s chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms, the vast majority of which have never been explored by science, creating a database of chemical biodiversity: the library of life. By growing, organizing, translating, and searching this unique library, Enveda learns from life’s evolved solutions to address today’s most pressing medical needs. For more information, visit https://enveda.com/.

Contacts

Media Contacts

Enveda
Natasha Alimchandani
natasha@enveda.com
(310) 428-6414

KKH Advisors
Kimberly Ha
kimberly.ha@kkhadvisors.com
(917) 291-5744

(c)2025 Business Wire, Inc., All rights reserved.